Publications

Pflueger D, Rickman DS, Sboner A, Perner S, Lafargue CJ, Svensson MA, Moss BJ, Kitabayashi N, Pan Y, de la Taille A et al..  2009.  N-myc downstream regulated gene 1 (NDRG1) is fused to ERG in prostate cancer.. Neoplasia. 11(8):804-11.

Mosquera J-M, Mehra R, Regan MM, Perner S, Genega EM, Bueti G, Shah RB, Gaston S, Tomlins SA, Wei JT et al..  2009.  Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States.. Clin Cancer Res. 15(14):4706-11.

Mosquera J-M, Mehra R, Regan MM, Perner S, Genega EM, Bueti G, Shah RB, Gaston S, Tomlins SA, Wei JT et al..  2009.  Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States.. Clin Cancer Res. 15(14):4706-11.

Rickman DS, Pflueger D, Moss B, VanDoren VE, Chen CX, de la Taille A, Kuefer R, Tewari AK, Setlur SR, Demichelis F et al..  2009.  SLC45A3-ELK4 is a novel and frequent erythroblast transformation-specific fusion transcript in prostate cancer.. Cancer Res. 69(7):2734-8.

Perner S, Wagner PL, Soltermann A, LaFargue C, Tischler V, Weir BA, Weder W, Meyerson M, Giordano TJ, Moch H et al..  2009.  TTF1 expression in non-small cell lung carcinoma: association with TTF1 gene amplification and improved survival.. J Pathol. 217(1):65-72.

Setlur SR, Mertz KD, Hoshida Y, Demichelis F, Lupien M, Perner S, Sboner A, Pawitan Y, Andrén O, Johnson LA et al..  2008.  Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer.. J Natl Cancer Inst. 100(11):815-25.

Setlur SR, Mertz KD, Hoshida Y, Demichelis F, Lupien M, Perner S, Sboner A, Pawitan Y, Andrén O, Johnson LA et al..  2008.  Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer.. J Natl Cancer Inst. 100(11):815-25.

Mertz KD, Setlur SR, Dhanasekaran SM, Demichelis F, Perner S, Tomlins S, Tchinda J, Laxman B, Vessella RL, Beroukhim R et al..  2007.  Molecular characterization of TMPRSS2-ERG gene fusion in the NCI-H660 prostate cancer cell line: a new perspective for an old model.. Neoplasia. 9(3):200-6.

Mertz KD, Setlur SR, Dhanasekaran SM, Demichelis F, Perner S, Tomlins S, Tchinda J, Laxman B, Vessella RL, Beroukhim R et al..  2007.  Molecular characterization of TMPRSS2-ERG gene fusion in the NCI-H660 prostate cancer cell line: a new perspective for an old model.. Neoplasia. 9(3):200-6.

Bismar TA, Demichelis F, Riva A, Kim R, Varambally S, He L, Kutok J, Aster JC, Tang J, Kuefer R et al..  2006.  Defining aggressive prostate cancer using a 12-gene model.. Neoplasia. 8(1):59-68.

Perner S, Demichelis F, Beroukhim R, Schmidt FH, Mosquera J-M, Setlur S, Tchinda J, Tomlins SA, Hofer MD, Pienta KG et al..  2006.  TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer.. Cancer Res. 66(17):8337-41.

Perner S, Demichelis F, Beroukhim R, Schmidt FH, Mosquera J-M, Setlur S, Tchinda J, Tomlins SA, Hofer MD, Pienta KG et al..  2006.  TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer.. Cancer Res. 66(17):8337-41.

Dimitroff CJ, Descheny L, Trujillo N, Kim R, Nguyen V, Huang W, Pienta KJ, Kutok JL, Rubin MA.  2005.  Identification of leukocyte E-selectin ligands, P-selectin glycoprotein ligand-1 and E-selectin ligand-1, on human metastatic prostate tumor cells.. Cancer Res. 65(13):5750-60.

Varambally S, Yu J, Laxman B, Rhodes DR, Mehra R, Tomlins SA, Shah RB, Chandran U, Monzon FA, Becich MJ et al..  2005.  Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression.. Cancer Cell. 8(5):393-406.

Kim R, Demichelis F, Tang J, Riva A, Shen R, Gibbs DF, Mahavishno V, Chinnaiyan AM, Rubin MA.  2005.  Internet-based Profiler system as integrative framework to support translational research.. BMC Bioinformatics. 6:304.

Dhanasekaran SMohan, Dash A, Yu J, Maine IP, Laxman B, Tomlins SA, Creighton CJ, Menon A, Rubin MA, Chinnaiyan AM.  2005.  Molecular profiling of human prostate tissues: insights into gene expression patterns of prostate development during puberty.. FASEB J. 19(2):243-5.

Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun X-W, Varambally S, Cao X, Tchinda J, Kuefer R et al..  2005.  Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer.. Science. 310(5748):644-8.

Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun X-W, Varambally S, Cao X, Tchinda J, Kuefer R et al..  2005.  Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer.. Science. 310(5748):644-8.

Kumar-Sinha C, Shah RB, Laxman B, Tomlins SA, Harwood J, Schmitz W, Conzelmann E, Sanda MG, Wei JT, Rubin MA et al..  2004.  Elevated alpha-methylacyl-CoA racemase enzymatic activity in prostate cancer.. Am J Pathol. 164(3):787-93.

Hofer MD, Fecko A, Shen R, Setlur SR, Pienta KG, Tomlins SA, Chinnaiyan AM, Rubin MA.  2004.  Expression of the platelet-derived growth factor receptor in prostate cancer and treatment implications with tyrosine kinase inhibitors.. Neoplasia. 6(5):503-12.

Santagata S, Demichelis F, Riva A, Varambally S, Hofer MD, Kutok JL, Kim R, Tang J, Montie JE, Chinnaiyan AM et al..  2004.  JAGGED1 expression is associated with prostate cancer metastasis and recurrence.. Cancer Res. 64(19):6854-7.

Rubin MA, Varambally S, Beroukhim R, Tomlins SA, Rhodes DR, Paris PL, Hofer MD, Storz-Schweizer M, Kuefer R, Fletcher JA et al..  2004.  Overexpression, amplification, and androgen regulation of TPD52 in prostate cancer.. Cancer Res. 64(11):3814-22.